Page 2 - Bruce Cree News Today

-- Separate analysis also being presented at ECTRIMS 2022 reinforces the efficacy of UPLIZNA in patients with genetic variations -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data

Press release content from Business Wire. The AP news staff was not involved in its creation.

Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests.

-- Data being presented at the CMSC Annual Meeting demonstrates UPLIZNA may reduce attack risk and disability among populations with genetic variables typically linked to poor treatment response

-- Separate analysis being presented at the AAN Annual Meeting shows UPLIZNA reduced pain associated with NMOSD over three years -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation

In a study of members of the Armed Forces, people who developed multiple sclerosis first had Epstein-Barr virus.

A new indirect comparison of three new FDA-approved treatment options for aquaporin4+ neuromyelitis optica has suggested that eculizumab is the most effective. But many limitations have been raised.

The new anti-CD20 monoclonal antibody showed significant improvement in the multiple sclerosis functional composite (MSFC) score, a measure of disability, compared with teriflunomide.

Treatment with Zeposia demonstrated a low annualized relapse rate of 0.103 and more than 70% of patients were relapse-free at four years Safety was consistent with prior findings and the established safety profile of Zeposia in up to 5 years of follow-up Bristol Myers Squibb today announced interim results from the Phase 3 open-label extension trial DAYBREAK, demonstrating the long-term efficacy and safety profile ...

Horizon Therapeutics: New Long-Term Data for UPLIZNA (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD) -- UPLIZNA continues to lower the rate of NMOSD attacks throughout the four-year open-label period (OLP) -- -- Results from NMOSD patient survey describe long and daunting journey to diagnosis -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data being presented at the American Academy of Neurologys 73rd Annual Me...